MedTrace Logo

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

NCT06996782 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2026-05-01

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.

Conditions

Interventions

DRUG

Rilvegostomig

Rilvegostomig will be administered as an intravenous (IV) infusion.

DRUG

Cisplatin

Cisplatin will be administered as SoC as an IV infusion.

DRUG

Carboplatin

Carboplatin will be administered as SoC as an IV infusion.

DRUG

Pemetrexed

Pemetrexed will be administered as SoC as an IV infusion.

DRUG

Paclitaxel

Paclitaxel will be administered as SoC as an IV infusion.

DRUG

Nab-paclitaxel

Nab-paclitaxel will be administered as SoC as an IV infusion.

DRUG

Ramucirumab

Ramucirumab will be administered as an IV infusion.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-24
Primary Completion
2029-02-23
Completion
2029-02-23
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Brazil
  • China
  • France
  • Georgia
  • Germany
  • Italy
  • Japan
  • Malaysia
  • Moldova
  • Netherlands
  • Peru
  • Poland
  • Serbia
  • South Korea
  • Spain
  • Taiwan
  • Thailand
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06996782 on ClinicalTrials.gov